Over the past few years, increasing interest in the role of autoantibodies against myelin oligodendrocyte glycoprotein (MOG-abs) as a new candidate biomarker in demyelinating central nervous system diseases has arisen. MOG-abs have now consistently been identified in a variety of demyelinating syndromes, with a predominance in paediatric patients. The clinical spectrum of these MOG-ab-associated disorders (MOGAD) is still expanding and differs between paediatric and adult patients.
Prof Kumaran Deiva (French Reference Network of Rare Inflammatory Brain and Spinal Diseases, Le Kremlin Bicêtre Hospital, France and European Reference Network-RITA) has taken part in the coordination work of a set of 5 publications.
Consult the articles
Part 1: Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders
Part 2: Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders
Part 3: Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated
disorders
Part 4: Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated
disorders
Part 5: Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated
disorders